Skip to main content

Table 2 Factors influencing LRFS, EFS and OS (Cox proportional Hazard Model)

From: Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution

Analysis using locoregional recurrence free survival (type 1)
Factors Univariate analysis Multivariate analysis
  HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.794 0.221 to 2.846 0.717 - - -
Tumour: pT1-2 vs pT3-4 0.273 0.095 to 0.787 0.016 0.326 0.11 to 0.963 0.043
SBR grade: 1-2 vs 3 0.692 0.232 to 2.066 0.509 - - -
ER status: positive vs negative 0.359 0.125 to 1.036 0.058 0.387 0.13 to 1.157 0.079
Age: ≥ 40 vs < 40 1.288 0.359 to 4.618 0.697 - - -
Regimen: anthracycline vs CMF 0.454 0.157 to 1.308 0.143 0.347 0.114 to 1.053 0.062
Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1 0.466 0.223 to 1.987 0.439 0.587 0.244 to 1.414 0.235
Analysis using event free survival
  Univariate analysis Multivariate analysis
  HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.406 0.216 to 0.766 0.004 0.397 0.216 to 0.779 0.006
Tumour: pT1-2 vs pT3-4 0.552 0.356 to 0.855 0.007 0.624 0.392 to 0.993 0.047
SBR grade: 1-2 vs 3 0.801 0.508 to 1.265 0.341 0.971 0.598 to 1.576 0.906
ER status: positive vs negative 0.674 0.438 to 1.038 0.058 0.64 0.404 to 1.015 0.058
Age: ≥ 40 vs < 40 1.183 0.717 to 1.951 0.511 - - -
Regimen: anthracycline vs CMF 0.665 0.435 to 1.016 0.057 0.558 0.354 to 0.879 0.012
Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1 0.696 0.445 to 1.089 0.11 0.625 0.39 to 1.002 0.051
Analysis using overall survival
  Univariate analysis Multivariate analysis
  HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.298 0.137 to 0.651 0.002 0.317 0.144 to 0.697 0.004
Tumour: pT1-2 vs pT3-4 0.619 0.381 to 1.005 0.052 0.719 0.429 to 1.208 0.213
SBR grade: 1-2 vs 3 0.694 0.427 to 1.130 0.142 0.781 0.466 to 1.309 0.347
ER status: positive vs negative 0.737 0.458 to 1.186 0.208 0.714 0.429 to 1.189 0.196
Age: ≥ 40 vs < 40 1.260 0.723 to 2.197 0.414 - - -
Regimen: anthracycline vs CMF 0.708 0.445 to 1.128 0.143 0.603 0.367 to 0.99 0.046
Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1 0.768 0.468 to 1.261 0.297 0.713 0.423 to 1.201 0.203
  1. Abbreviations: HR = hazard ratio; CI = confidence interval; SBR = Scarf-Bloom-Richardson; ER = estrogen receptor; CT = chemotherapy; RT = radiotherapy